 Home > Active Ingredient News > Antitumor Therapy > J Thorac Oncol: Lorlatinib is still effective after progression in patients with ALK+ NSCLC

J Thorac Oncol: Lorlatinib is still effective after progression in patients with ALK+ NSCLC

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

parkinson's disease treatment drugs

diarrheal disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a study was published in the Journal of Thoracic Oncology, mainly based on a retrospective analysis of the data of a phase II clinical study (NCT01970865), evaluating the continuation of Lorlatinib after progression in ALK+ NSCLC patients treated with Lorlatinib (Lorlatinib).
curative effect
.

NSCLC

A retrospective analysis of the clinical benefit of continuation of lorlatinib in patients with progression (LBPD) in an ongoing phase II trial (NCT01970865)
.

Patients who had previously used only crizotinib as an ALK TKI were group A (n = 28); patients who had previously used ≥1 second-generation ALK TKIs were group B (n = 74)

A retrospective analysis of the clinical benefit of continuation of lorlatinib in patients with progression (LBPD) in an ongoing phase II trial (NCT01970865)

The median follow-up time for groups A and B was 35.

Compared with non-LBPD patients, LBPD patients had less extracranial progression (group A: 71.
4% vs 100.
0%; group B: 67.
9% vs 94.
4%)
.

In addition, in group A patients, LBPD patients had more target lesion progression (76.

Compared with non-LBPD patients, LBPD patients had less extracranial progression (group A: 71.

About a quarter of non-LBPD patients did not receive any follow-up treatment

The overall median duration of treatment was 32.

Among patients in group A, the overall median overall survival (OS) was not reached (NR) in patients with LBPD, while the overall median overall survival in patients without LBPD was 24.
4 months (95%CI 12.
1-NR); in patients in group B , the overall median OS was 26.
5 months (95% CI 18.
7-35.
5) for patients with LBPD and 14.
7 months (95% CI 9.
3-38.
5) for patients without LBPD
.

Among patients in group A, the overall median overall survival (OS) was not reached (NR) in patients with LBPD, while the overall median overall survival in patients without LBPD was 24.

In group A patients, the median OS after progression was not reached in LBPD patients, and the median OS after progression in non-LBPD patients was 8.
0 months (95% CI 1.
5-NR); in group B patients, the median OS after progression in LBPD patients The median OS after progression was 5.
3 months (95% CI 2.
8-14.
3) in non-LBPD patients
.

In group A patients, the median OS after progression was not reached in LBPD patients, and the median OS after progression in non-LBPD patients was 8.

In conclusion, the study shows that Lorlatinib (lorlatinib) treatment of ALK+ NSCLC patients after progression is an optional strategy

Original source:

Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A.

Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A.
Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.
J Thorac Oncol.
2022 Jan 10: S1556-0864(21)03417-1.
doi: 10.
1016/j.
jtho.
2021.
12.
011.
Epub ahead of print.
PMID: 35026476.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.